| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-08-16 08:41:04 UTC |
|---|
| Update Date | 2022-03-07 02:49:04 UTC |
|---|
| HMDB ID | HMDB0000608 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Cobalt |
|---|
| Description | Cobalt has a molecular weight of 58.9 and an atomic number of 27. In the Periodic Table, close to other transition metals, it is situated in group 8, together with rhodium and iridium and it can occur in four oxidation states (0, +2, +3 and +4). The +2 and the ground state are the most common. Cobalt occurs in the minerals cobaltite (Co, Fe) AsS, smaltite (CoAs2), and erythrite Co3(AsO4)2.8H2O, and is often associated with nickel, silver, lead, copper, and iron ores, from which it is most frequently obtained as a by-product. Depending on the considered species, cobalt has multiple industrial applications including the production of alloys and hard metal, diamond polishing, drying agents, pigments and catalysts. Hard metal or cemented carbide is a powder metallurgical product consisting of hard, wear-resistant carbide particles bound together (cemented) with a ductile metal binder (i.e. metallic Co) by liquid phase sintering. Tungsten carbide (WC) is produced by mixing tungsten powder with pure carbon powder at high temperature; hereafter WC is mixed with Co powder to which paraffin is added as a binder. Depending on specific requirements related to their use, hard metals might additionally contain small quantities of chromium, niobium, molybdenum, titanium, tantalum or vanadium carbides. Inhalation and skin contact are the main occupational exposure routes. Occupational exposure to cobalt may result in adverse health effects in different organs or tissues, including the respiratory tract, the skin, the hemapoietic tissues, the myocardium or the thyroid gland. In addition, teratogenic and carcinogenic effects have been observed in experimental systems and/or in humans. For the general population, the diet constitutes the main route of exposure to cobalt, since it is an essential component of Vitamin B12 (hydroxycolalamin). Cobalt functions as a co-factor in enzyme catalysed reactions and is involved in the production of erythropoietin, a hormone that stimulates the formation of erythrocytes. This last property of cobalt was applied in the past as a therapy for anaemia. The carcinogenic potential of cobalt and its compounds was evaluated in 1991 by the International Agency for Research on Cancer (IARC), which concluded that there was inadequate evidence for carcinogenicity in humans (lung cancer) but sufficient evidence in experimental animal studies. In most experimental studies considered, the routes of exposure were, however, of questionable relevance for cancer risk assessment in humans for example, local sarcomas after intra-muscular injection. The general conclusion was that cobalt and its compounds are possibly carcinogenic to humans (group 2B). Since this evaluation, additional data have been accumulated which generally indicate that, depending on the considered cobalt species, different outcomes regarding toxicity, mutagenicity and carcinogenicity can be observed. Physiologically, it exists as an ion in the body. Co(II) ions are genotoxic in vitro and in vivo, and carcinogenic in rodents. Co metal is genotoxic in vitro. Hard metal dust, of which occupational exposure is linked to an increased lung cancer risk, is proven to be genotoxic in vitro and in vivo. Possibly, production of active oxygen species and/or DNA repair inhibition are mechanisms involved. Given the recently provided proof for in vitro and in vivo genotoxic potential of hard metal dust, the mechanistic evidence of elevated production of active oxygen species and the epidemiological data on increased cancer risk, it may be advisable to consider the possibility of a new evaluation by IARC.(PMID: 14643417 ). |
|---|
| Structure | |
|---|
| Synonyms | | Value | Source |
|---|
| Co(II) | ChEBI | | CO2+ | ChEBI | | Co(2+) | ChEBI | | COBALT (II) ion | ChEBI | | Cobalt(2+) ion | ChEBI | | Cobalt(II) cation | ChEBI | | Cobaltous ion | ChEBI | | Cobalt(2+) | Kegg | | Aquacat | HMDB | | Co | HMDB | | Cobalt-59 | HMDB | | Cobatope-57 | HMDB | | Kobalt | HMDB | | Super cobalt | HMDB |
|
|---|
| Chemical Formula | Co |
|---|
| Average Molecular Weight | 58.9332 |
|---|
| Monoisotopic Molecular Weight | 58.933200194 |
|---|
| IUPAC Name | lambda2-cobalt(2+) ion |
|---|
| Traditional Name | lambda2-cobalt(2+) ion |
|---|
| CAS Registry Number | 7440-48-4 |
|---|
| SMILES | [Co++] |
|---|
| InChI Identifier | InChI=1S/Co/q+2 |
|---|
| InChI Key | XLJKHNWPARRRJB-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom. |
|---|
| Kingdom | Inorganic compounds |
|---|
| Super Class | Homogeneous metal compounds |
|---|
| Class | Homogeneous transition metal compounds |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Homogeneous transition metal compounds |
|---|
| Alternative Parents | Not Available |
|---|
| Substituents | - Homogeneous transition metal
|
|---|
| Molecular Framework | Not Available |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 1495 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 300.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 986.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 470.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 210.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 388.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 250.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 356.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 455.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 697.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 734.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 216.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 801.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 325.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 401.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 723.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 410.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 314.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| Spectra |
|---|
| MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 10V, Positive-QTOF | splash10-0a4i-9000000000-5ec55e9e276ff34b918f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 20V, Positive-QTOF | splash10-0a4i-9000000000-5ec55e9e276ff34b918f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 40V, Positive-QTOF | splash10-0a4i-9000000000-5ec55e9e276ff34b918f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 10V, Negative-QTOF | splash10-0a4i-9000000000-c4eed668d3af388c4a95 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 20V, Negative-QTOF | splash10-0a4i-9000000000-c4eed668d3af388c4a95 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cobalt 40V, Negative-QTOF | splash10-0a4i-9000000000-c4eed668d3af388c4a95 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | Not Available |
|---|
| Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
|---|
| Tissue Locations | |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 0.00183 (0.00067 - 0.00460) uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 0.0031 +/- 0.0017 uM | Elderly (>65 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 0.00067 - 0.0080 uM | Adult (>18 years old) | Both | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.01+/-0.005 (0.001-0.04) uM | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected and Quantified | 0.006 +/- 0.002 uM | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected and Quantified | 0.509 +/- 0.509 uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 0.339 +/- 0.509 uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 0.119 +/- 0.0339 uM | Adult (>18 years old) | Not Specified | Normal | | details | | Urine | Detected and Quantified | 0.00081 +/- 0.00053 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | - Geigy Scientific ...
- West Cadwell, N.J...
- Basel, Switzerlan...
| details | | Urine | Detected and Quantified | 0.0014 (0.0001-0.014) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 0.000712 (0.000671-0.000756) umol/mmol creatinine | Adult (>18 years old) | Not Specified | Normal | | details | | Urine | Detected and Quantified | 0.00111 (0.00103-0.00119) umol/mmol creatinine | Children (1-13 years old) | Not Specified | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 0.0019 +/- 0.0010 uM | Adult (>18 years old) | Both | Alzheimer's disease | | details | | Blood | Detected and Quantified | 0.0037 +/- 0.0017 uM | Adult (>18 years old) | Both | Multiple sclerosis | | details | | Blood | Detected and Quantified | 0.0019 +/- 0.0085 uM | Adult (>18 years old) | Both | Parkinson's disease | | details | | Saliva | Detected and Quantified | 2.545 +/- 0.170 uM | Adult (>18 years old) | Not Specified | Oral squamous cell carcinoma | | details | | Saliva | Detected and Quantified | 2.715 +/- 0.848 uM | Adult (>18 years old) | Not Specified | Oral squamous cell carcinoma | | details | | Saliva | Detected and Quantified | 2.0362 +/- 0.509 uM | Adult (>18 years old) | Not Specified | Oral squamous cell carcinoma | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Alzheimer's disease |
|---|
- Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A: Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita. 2005;41(2):197-203. [PubMed:16244393 ]
| | Multiple sclerosis |
|---|
- Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6. [PubMed:16244395 ]
| | Parkinson's disease |
|---|
- Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B: Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita. 2005;41(2):189-95. [PubMed:16244392 ]
|
|
|---|
| Associated OMIM IDs | |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB003581 |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 94546 |
|---|
| KEGG Compound ID | C00175 |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Cobalt |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | 104729 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 48828 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | COBALT2 |
|---|
| MarkerDB ID | MDB00000200 |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| Material Safety Data Sheet (MSDS) | Download (PDF) |
|---|
| General References | - Liden C, Skare L, Lind B, Nise G, Vahter M: Assessment of skin exposure to nickel, chromium and cobalt by acid wipe sampling and ICP-MS. Contact Dermatitis. 2006 May;54(5):233-8. [PubMed:16689805 ]
- Larese Filon F, Maina G, Adami G, Venier M, Coceani N, Bussani R, Massiccio M, Barbieri P, Spinelli P: In vitro percutaneous absorption of cobalt. Int Arch Occup Environ Health. 2004 Feb;77(2):85-9. Epub 2003 Jun 19. [PubMed:12819972 ]
- Fisher JW: A quest for erythropoietin over nine decades. Annu Rev Pharmacol Toxicol. 1998;38:1-20. [PubMed:9597146 ]
- Morales Concepcion JC, Cordies Jackson E, Sandin Hernandez N, Reno Cespedes J, Moreno Diaz ME: [Metachronous bilateral Wilms' tumor]. Arch Esp Urol. 2000 Apr;53(3):245-7. [PubMed:10851730 ]
- De Boeck M, Kirsch-Volders M, Lison D: Cobalt and antimony: genotoxicity and carcinogenicity. Mutat Res. 2003 Dec 10;533(1-2):135-52. [PubMed:14643417 ]
|
|---|